Alvotech
General ticker "ALVO" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $2.9B (TTM average)
Alvotech does not follow the US Stock Market performance with the rate: -18.1%.
Estimated limits based on current volatility of 1.9%: low 4.78$, high 4.96$
Factors to consider:
- Total employees count: 947 as of 2022
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.03$, 14.86$]
- 2025-12-31 to 2026-12-31 estimated range: [4.83$, 12.22$]
Financial Metrics affecting the ALVO estimates:
- Negative: with PPE of -19.0 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of -7.07 <= 0.04
- Positive: 7.54 < Operating profit margin, % of 14.22
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of -33.79 <= 19.35
- Positive: Investing cash flow per share per price, % of -0.56 > -0.62
- Positive: Industry inventory ratio change (median), % of -1.67 <= -0.18
Short-term ALVO quotes
Long-term ALVO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $83.03MM | $91.43MM | $489.68MM |
| Operating Expenses | $429.47MM | $446.29MM | $420.04MM |
| Operating Income | $-346.44MM | $-354.86MM | $69.64MM |
| Non-Operating Income | $-205.21MM | $-296.19MM | $-287.21MM |
| Interest Expense | $91.44MM | $134.82MM | $157.60MM |
| R&D Expense | $180.62MM | $210.83MM | $171.31MM |
| Income(Loss) | $-551.65MM | $-651.05MM | $-217.56MM |
| Taxes | $-38.07MM | $-99.32MM | $14.30MM |
| Profit(Loss)* | $-513.58MM | $-551.73MM | $-231.86MM |
| Stockholders Equity | $-564.42MM | $-932.49MM | $-412.77MM |
| Inventory | $71.47MM | $74.43MM | $127.89MM |
| Assets | $828.44MM | $950.09MM | $1,221.40MM |
| Operating Cash Flow | $-312.39MM | $-312.19MM | $-236.84MM |
| Capital expenditure | $49.00MM | $46.47MM | $57.00MM |
| Investing Cash Flow | $-63.54MM | $-46.34MM | $-18.87MM |
| Financing Cash Flow | $424.91MM | $301.32MM | $297.31MM |
| Earnings Per Share** | $-2.60 | $-2.43 | $-0.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.